Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium (3-oxo-(17r)-17-28-norolean-12(13)-en)-2-oxoethyl-phosphonate
- Development stage
- Preclinical
- Lead developer
- Victor Babeș University of Medicine and Pharmacy Timișoara
- Modality
- Small Molecules
01
Overview
Sodium (3-oxo-(17r)-17-28-norolean-12(13)-en)-2-oxoethyl-phosphonate is a semisynthetic pentacyclic triterpenoid derivative of oleanonic acid (the 3-oxo derivative of oleanolic acid). It features a sodium methylphosphonate moiety at the C17 position, a modification designed to improve the pharmacokinetic profile and bioavailability of the parent triterpenoid. In preclinical evaluations using the B164A5 murine melanoma cell line, this derivative demonstrated significant dose-dependent antiproliferative and anti-migratory activities. The compound appears to induce apoptosis, as evidenced by increased nuclear condensation in related oleanane derivatives, while maintaining a safety profile similar to its parent triterpenoids, as indicated by LDH and HET-CAM assays. It is currently being researched as a potential therapeutic candidate for the treatment of melanoma.
- Other names
- sodium (3-oxo-olean-12-en-28-oyloxymethyl)phosphonateoleanonic acid phosphonate derivative
Beyond the preview
Go deeper on sodium (3-oxo-(17r)-17-28-norolean-12(13)-en)-2-oxoethyl-phosphonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium (3-oxo-(17r)-17-28-norolean-12(13)-en)-2-oxoethyl-phosphonate.